Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Authors :: Marijo Bilusic
Jeffrey Schlom
Ravi A. Madan
Christopher R. Heery
Claudia Palena
James L. Gulley
Margaret Elena Gatti-Mays
Julie Collins
Julius Strauss
Renee N. Donahue
Source :: Journal of Clinical Oncology. 36:3091-3091
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 3091Background: BMS-986253 is a novel fully human monoclonal antibody that binds to and inhibits IL-8, a chemokine that promotes immune escape and tumor progression. High serum IL-8 levels correlat...

Subjects :: 0301 basic medicine
Cancer Research
Chemokine
biology
business.industry
medicine.drug_class
High serum
Immune escape
Monoclonal antibody
03 medical and health sciences
030104 developmental biology
Oncology
Tumor progression
Cancer research
biology.protein
Medicine
In patient
Interleukin 8
business

Tools